Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Orelabrutinib + R-CHOP in Treatment-naïve Mantle Cell Lymphoma
NCT05051891Phase 3Completed
- Sponsor
- InnoCare Pharma
- Start
- Dec 2021
- Primary completion
- Jun 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of orelabrutinib in mantle cell lymphoma (MCL), sponsored by InnoCare Pharma. Started Dec 2021; status: completed.
02
Drugs
orelabrutinib
03
Conditions
mantle cell lymphoma (MCL)
Beyond the preview
Go deeper on NCT05051891.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05051891.